Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14512715 | 1.00 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5584412 | 0.88 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL14512693 | 0.88 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5146859 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL14512703 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL14512682 | 0.86 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5145103 | 0.86 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL14512689 | 0.85 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5145366 | 0.85 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5584740 | 0.85 | CNR1 (0.85) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | claimed |
| CN-1956949-A | Substituted sulfonamides | MERCK & CO INC (US) | 2007-05-02 | — | — | CN | claimed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105914-A1 | Substituted sulfonamides | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.